Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott Japan and Eisai are set to introduce Lipacreon Capsules 150 mg and Lipacreon Granules 300mg Sachets (pancrelipase) on 30 August in Japan for pancreatic exocrine insufficiency (PEI) due to chronic pancreatitis, pancreatectomy, cystic fibrosis and other conditions.
Subscribe to our email newsletter
When compared with Japanese Pharmacopoeia-listed pancreatin, the titer per unit weight of Lipacreon is approximately 8 times that of lipase, approximately 7 times that of protease and approximately 6 times that of amylase, claims Abbott Japan.
In addition, because the drug has been designed with an optimal granule diameter to ensure that it passes into the duodenum, it is expected to effectively stimulate digestion and absorption in PEI patients, thereby improving their nutritional health.
The results of a placebo-controlled double-blind study carried out in Japan in patients with PEI due to chronic pancreatitis or pancreatectomy showed that Lipacreon improved fat absorption, an indicator used to measure nutritional status.
The drug also demonstrated significant improvements in nutritional endpoints in a long term study.